Companies

Novo Nordisk Stock Plummets After New Weight-Loss Drug Falls Short Against Rival

The test drug, CagriSema, failed to match Eli Lilly’s Zepbound after an 84-week trial, the company said.
Google LogoMark Us Preferred on Google
Novo Nordisk Stock Plummets After New Weight-Loss Drug Falls Short Against Rival
The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters in Bagsvaerd, Denmark, on Feb. 1, 2017. Liselotte Sabroe/Scanpix Denmark/AFP via Getty Images
Mary Prenon
Mary Prenon
Freelance Reporter
|Updated:
0:00
Stock prices for Denmark-based Novo Nordisk dropped by more than 15 percent on Feb. 23 after the global healthcare firm announced disappointing results from a clinical trial of CagriSema.

Known for its Ozempic injectable medication for treating diabetes and obesity, Novo Nordisk’s newest pharmaceutical just completed its phase 3 trial, called REDEFINE 4, an 84-week trial test of CagriSema, a combination of cagrilintide 2.4 mg and semaglutide 2.4 mg injectable.

Google LogoMark Us Preferred on Google
Mary Prenon
Mary Prenon
Freelance Reporter
Mary T. Prenon covers real estate and business. She has been a writer and reporter for over 25 years with various print and broadcast media in New York.